CSIMarket
 


Aim Immunotech Inc   (AIM)
Other Ticker:  
 

Aim Immunotech Inc 's Tangible Leverage Ratio

AIM's quarterly Tangible Leverage Ratio and Total Liabilities, Tangible Equity growth


Due to net new borrowings of 68.31%, Tangible Leverage Ratio fell to 0.22, below the Aim Immunotech Inc 's average Tangible Leverage Ratio.

Within Biotechnology & Pharmaceuticals industry in the third quarter 2023, 45 other companies have achieved lower Tangible Leverage Ratio than Aim Immunotech Inc in the III Quarter 2023. While Tangible Leverage Ratio total ranking has deteriorated compared to the second quarter 2023 from 206 to 553 .

Explain Tangible Leverage Ratio?
What is AIM Market Share?
What are AIM´s Total Liabilities?


AIM Tangible Leverage Ratio (Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Tangible Equity Change -49.74 % -39.92 % -35.51 % -33.47 % -32.42 %
Y / Y Total Liabilities Change 65.53 % 120.68 % 134.99 % 86.01 % 272.64 %
Tangible Leverage Ratio MRQ 0.22 0.1 0.05 0.03 0.07
AIM's Total Ranking # 553 # 206 # 78 # 0 # 170
Seq. Tangible Equity Change -27.22 % -15.09 % -9.41 % -10.21 % -13.01 %
Seq. Total Liabilities Change 68.31 % 61.48 % 40.24 % -56.57 % 124.38 %



Tangible Leverage Ratio third quarter 2023 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 46
Healthcare Sector # 278
Overall Market # 553


Tangible Leverage Ratio Statistics
High Average Low
1.45 0.39 0.01
(Jan 31 2012)   (Dec 31 2021)




Financial Statements
Aim Immunotech Inc 's Tangible Equity $ 20 Millions Visit AIM's Balance sheet
Aim Immunotech Inc 's Total Liabilities $ 5 Millions Visit AIM's Balance sheet
Source of AIM's Sales Visit AIM's Sales by Geography


Cumulative Aim Immunotech Inc 's Tangible Leverage Ratio

AIM's Tangible Leverage Ratio for the trailling 12 Months

AIM Tangible Leverage Ratio

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Tangible Equity TTM Growth -49.74 % -39.92 % -35.51 % -33.47 % -32.42 %
Y / Y Total Liabilities TTM Growth 65.53 % 120.68 % 134.99 % 86.01 % 272.64 %
Tangible Leverage Ratio TTM 0.08 0.06 0.04 0.03 0.03
Total Ranking TTM # 2 # 155 # 55 # 0 # 44
Seq. Tangible Equity TTM Growth -27.22 % -15.09 % -9.41 % -10.21 % -13.01 %
Seq. Total Liabilities TTM Growth 68.31 % 61.48 % 40.24 % -56.57 % 124.38 %


On the trailing twelve months basis Due to the net new borrowings of 68.31% during the trailing twelve months finishing in the III Quarter 2023, cumulativeTangible Leverage Ratio improved to 0.08, below the Aim Immunotech Inc 's average Tangible Leverage Ratio.
Tangible Leverage Ratio is the average cumulative value over the last four quarters.

Among companies in the Biotechnology & Pharmaceuticals industry 45, during the past 12 months, other companies have achieved lower Tangible Leverage Ratio than Aim Immunotech Inc . While Tangible Leverage Ratio total ranking has improved so far to 2, from total ranking in previous 12 month period at 155.

Explain Tangible Leverage Ratio?
What is AIM Market Share?
What are AIM´s Total Liabilities?

TTM Tangible Leverage Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 46
Healthcare Sector # 278
Within the Market # 2


trailing twelve months Tangible Leverage Ratio Statistics
High Average Low
1.45 0.39 0.01
(Jan 31 2012)   (Dec 31 2021)




Companies with similar Tangible Leverage Ratio in the quarter ending Sep 30 2023, within Biotechnology & Pharmaceuticals Industry Tangible Leverage RatioSep 30 2023 MRQ Total LiabilitiesSep 30 2023 MRQ Tangible Equity
Elevation Oncology inc   0.60 $ 37.559  Millions$ 62.416  Millions
Senti Biosciences Inc   0.59 $ 48.830  Millions$ 82.936  Millions
Vericel Corporation  0.58 $ 113.745  Millions$ 197.349  Millions
Aligos Therapeutics Inc   0.57 $ 31.031  Millions$ 54.821  Millions
Recursion Pharmaceuticals Inc   0.56 $ 192.858  Millions$ 345.758  Millions
Vaxart Inc   0.55 $ 34.121  Millions$ 62.541  Millions
C4 Therapeutics Inc   0.54 $ 116.989  Millions$ 216.024  Millions
Miromatrix Medical inc   0.51 $ 7.879  Millions$ 15.542  Millions
Seagen Inc   0.46 $ 954.716  Millions$ 2,055.495  Millions
Moderna Inc   0.45 $ 5,995.000  Millions$ 13,455.000  Millions
Neurocrine Biosciences Inc   0.43 $ 846.100  Millions$ 1,967.200  Millions
Scholar Rock Holding Corp  0.41 $ 69.489  Millions$ 167.665  Millions
Instil Bio Inc   0.40 $ 94.426  Millions$ 234.024  Millions
Editas Medicine Inc   0.40 $ 144.188  Millions$ 360.462  Millions
Tscan Therapeutics Inc   0.39 $ 65.380  Millions$ 168.961  Millions
Ikena Oncology Inc   0.39 $ 59.991  Millions$ 155.344  Millions
Iovance Biotherapeutics Inc   0.37 $ 167.839  Millions$ 450.398  Millions
Monte Rosa Therapeutics Inc   0.37 $ 67.579  Millions$ 184.524  Millions
Sophia Genetics Sa  0.36 $ 54.714  Millions$ 151.442  Millions
Bioatla Inc   0.36 $ 34.006  Millions$ 94.703  Millions
Cognition Therapeutics inc   0.34 $ 9.846  Millions$ 28.926  Millions
Passage Bio inc   0.34 $ 42.980  Millions$ 126.276  Millions
Organovo Holdings Inc   0.32 $ 2.705  Millions$ 8.456  Millions
Twist Bioscience Corporation  0.32 $ 152.971  Millions$ 483.138  Millions
Fusion Pharmaceuticals Inc   0.31 $ 58.740  Millions$ 188.471  Millions
Entera Bio Ltd   0.31 $ 1.927  Millions$ 6.236  Millions
Graphite Bio Inc   0.30 $ 62.209  Millions$ 204.019  Millions
Black Diamond Therapeutics Inc   0.28 $ 38.065  Millions$ 134.317  Millions
Adverum Biotechnologies Inc   0.28 $ 28.856  Millions$ 102.714  Millions
Solid Biosciences Inc   0.28 $ 40.367  Millions$ 144.361  Millions

Date modified: 2024-02-17T22:50:48+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com